Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster
- Roche opens access to pathology imaging tools to improve patient care
- Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®
- Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
- SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Research & Development
- COVID-19 nasal vaccine candidate effective at preventing disease transmission
- How a plant virus could protect and save your lungs from metastatic cancer
- Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population
- NIH scientists build a cellular blueprint of multiple sclerosis lesions
- First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
- No serious health effects linked to mRNA COVID-19 vaccines
- Blood vessels produce growth factor that promotes metastases
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA advances data, IT modernization efforts with new office of digital transformation
- ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines
- FDA approves first COVID-19 vaccine
- FDA approves new treatment for Pompe disease
- FDA approves first interchangeable biosimilar insulin product for treatment of diabetes